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The metalloid arsenic (As), a group 1 human 
carcinogen (International Agency for Research 
on Cancer 2004), is the second most com-
mon inorganic contaminant at Superfund 
sites [U.S. Environmental Protection Agency 
(EPA) 2001]. Hence, cancer risk associ-
ated with ingestion of As-contaminated soils 
(Calabrese et al. 1996; Davis et al. 1991; 
Dudka and Miller 1999) often drives risk 
assessments for human exposure to metal 
contaminants at Superfund sites (U.S. EPA 
2007c). With increasing urbanization, expo-
sure to As-contaminated soils grows more 
likely as residential areas extend into the vicin-
ity or, in some cases, intrude onto Superfund 
sites (Scheckel et al. 2009). Reliable analy-
sis of human health risks from ingestion of 
As-contaminated soil depends on estimat-
ing the bioavailability of As in the soil (U.S. 
EPA 1989). Current exposure estimates from 
ingestion of As-contaminated soils often do 
not consider differences between the bio-
availability of As in water and soil (Ehlers 
and Luthy 2003). The use of default values 
that assume equivalent bioavailabilities for 
As in the two matrices can overestimate risk 
associated with ingestion of As-contaminated 
soil (Bradham and Wentsel 2010; U.S. EPA 
2007b, 2007c). Speciation of As in soil, con-
centrations of other metals or metalloids, and 
other soil properties (e.g., pH and mineral-
ogy) can affect the bioavailability of soil As 
and the amount available for systemic dispo-
sition [Kelly et al. 2002; National Research 
Council (NRC) 2003; U.S. EPA 2007b]. 
Because even small adjustments in soil As 
bioavailability estimates can significantly 
affect estimated risk and cleanup goals (U.S. 
EPA 2007c), methods are needed that quickly 
and inexpensively provide accurate and reli-
able data that can be applied to cleanups of 
As-contaminated sites worldwide.
Studies of soil As bioavailability have used 
species as diverse as rodents, swine, and mon-
keys (Casteel et al. 1997; Freeman et al. 1995; 
Lorenzana et al. 1996; Nagar et al. 2009; Ng 
et al. 1998; Pascoe et al. 1994; Rees et al. 
2009; Roberts et al. 2002). Time and cost 
considerations may limit use of some species 
in bioavailability assays (U.S. EPA 2007a, 
2007b). In the present study, we chose the 
mouse as the test species because of low pur-
chase and husbandry costs, ease of handling, 
improved predictive value of data because of 
the feasibility of an increased sample size in 
assays, and the potential for widespread use 
of a mouse-based assay in many laboratories. 
Mice are well characterized physiologically 
and can be manipulated experimentally (e.g., 
altered dietary components, altered genotype) 
to determine the effects of biological variation 
on the gastrointestinal absorption of metals 
and metalloids. Extant data on gastrointesti-
nal absorption of ingested arsenicals facilitate 
use of the mouse as a test species in assays of 
soil As bioavailability (Hughes et al. 2003, 
2005, 2008). Although mice and humans dif-
fer in metabolism and disposition of arsenicals 
(Vahter 1999), similarities are sufficient to 
permit use of mouse data to create physiolog-
ically based pharmacokinetic models that can 
be scaled for humans (El-Masri and Kenyon 
2008; Evans et al. 2008; Gentry et al. 2004a, 
2004b; Hughes et al. 1999).
Use of complementary experimental 
approaches to assess bioavailability has been 
advocated as a strategy to develop models that 
reduce uncertainty in risk assessment (NRC 
2003). In this study, we linked in vivo and 
in vitro assays with physicochemical charac-
terization of soils in a unified approach to 
develop accurate and reliable methods for risk 
assessment of As-contaminated soils. Results 
for test soils and standard reference materials 
Address correspondence to K.D. Bradham, 109 TW 
Alexander Dr., MD-D205-05, Research Triangle 
Park, NC, USA. Telephone: (919) 541-9414. Fax: 
(919) 541-3527. E-mail: bradham.karen@epa.gov
Supplemental Material is available online (http://
dx.doi.org/10.1289/ehp.1003352).
We thank K. Herbin-Davis and B. Edwards for 
excellent technical assistance and the EPA Region 9 
Superfund program for their support. Materials 
Research Collaborative Access Team operations at 
Argonne National Laboratory are supported by the 
U.S. Department of Energy and institutional members.
The U.S. Environmental Protection Agency 
through its Office of Research and Development 
partially funded and collaborated in this research. 
The research described in this article has been sub-
jected to agency review and approved for publication.
The authors declare they have no actual or potential 
competing financial interests.
Received 16 December 2010; accepted 13 July 2011.
Relative Bioavailability and Bioaccessibility and Speciation of Arsenic 
in Contaminated Soils
Karen D. Bradham,1 Kirk G. Scheckel,2 Clay M. Nelson,1 Paul E. Seales,3 Grace E. Lee,3 Michael F. Hughes,3 
Bradley W. Miller,2 Aaron Yeow,4 Thomas Gilmore,1 Sophia M. Serda,5 Sharon Harper,1 and David J. Thomas3
1National Exposure Research Laboratory, Office of Research and Development, U.S. Environmental Protection Agency, Research 
Triangle Park, North Carolina, USA; 2National Risk Management Research Laboratory, Office of Research and Development, 
U.S. Environmental Protection Agency, Cincinnati, Ohio, USA; 3Integrated Systems Toxicology Division, National Health and 
Environmental Effects Research Laboratory, Office of Research and Development, U.S. Environmental Protection Agency, Research 
Triangle Park, North Carolina, USA; 4Science Advisory Board Staff Office, U.S. Environmental Protection Agency, Washington, DC, USA; 
5U.S. Environmental Protection Agency, Region 9, San Francisco, CA, USA
Ba c k g r o u n d: Assessment of soil arsenic (As) bioavailability may profoundly affect the extent 
of remediation required at contaminated sites by improving human exposure estimates. Because 
small adjustments in soil As bioavailability estimates can significantly alter risk assessments and 
remediation goals, convenient, rapid, reliable, and inexpensive tools are needed to determine soil As 
bioavailability.
oBjectives: We evaluated inexpensive methods for assessing As bioavailability in soil as a means to 
improve human exposure estimates and potentially reduce remediation costs.
Me t h o d s : Nine soils from residential sites affected by mining or smelting activity and two National 
Institute of Standards and Technology standard reference materials were evaluated for As bioavail-
ability, bioaccessibility, and speciation. Arsenic bioavailability was determined using an in vivo 
mouse model, and As bioaccessibility was determined using the Solubility/Bioavailability Research 
Consortium in vitro assay. Arsenic speciation in soil and selected soil physicochemical properties 
were also evaluated to determine whether these parameters could be used as predictors of As bio-
availability and bioaccessibility.
re s u l t s: In the mouse assay, we compared bioavailabilities of As in soils with that for sodium 
arsenate. Relative bioavailabilities (RBAs) of soil As ranged from 11% to 53% (mean, 33%). In vitro 
soil As bioaccessibility values were strongly correlated with soil As RBAs (R2 = 0.92). Among physi-
cochemical properties, combined concentrations of iron and aluminum accounted for 80% and 
62% of the variability in estimates of RBA and bioaccessibility, respectively. 
co n c l u s i o n: The multifaceted approach described here yielded congruent estimates of As bio-
availability and evidence of interrelations among physicochemical properties and bioavailability 
estimates.
key w o r d s : arsenic, bioaccessibility, bioavailability, gastrointestinal, human health, human health 
risk assessment, metalloid, soil physicochemical properties, speciation. Environ Health Perspect 
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(SRMs) suggest that concerted use of in vivo 
and in vitro methods combined with physi-
cochemical characterization of soils provides 
a stronger scientific basis for the refinement 
of risk assessments for As-contaminated soils. 
In addition, correlations between physico-
chemical properties of soils and estimates of 
As bioavailability and bioaccessibility indicate 
that use of physicochemical properties could 
profitably inform the refinement of both ani-
mal-based and in vitro assays.
Materials and Methods
Soil origin, processing, and physicochemi-
cal characterization. For full description of 
soil origin, processing, and physicochemical 
characterization, see Supplemental Material 
(http://dx.doi.org/10.1289/ehp.1003352). 
Soils used in this study were collected from 
sites affected by mining and smelter activities. 
Physicochemical properties were determined 
in duplicate samples of each soil.
Arsenic speciation in soils was examined 
using the Materials Research Collaborative 
Access Team’s beamline 10-ID (Sector 10, 
Advanced Photon Source, Argonne National 
Laboratory, Argonne, IL). A principal com-
ponent analysis coupled with linear combina-
tion fitting was used to identify the major As 
species in the samples. Linear combination 
fits were performed using X-ray absorption 
spectroscopy k2 space spectra from reference 
standards to As phases in the soil samples.
Arsenic concentrations in all soil and biologi-
cal samples were determined by Instrumental 
Neutron Activation Analysis (INAA) at the 
Department of Nuclear Engineering, North 
Carolina State University (Raleigh, NC; mean 
As mass detection limit, 0.035 μg). All bio-
availability and bioaccessibility calculations 
were based on INAA values.
Mouse  bioavailability  assay.  The 
Institutional Animal Care and Use Committee 
of the U.S. EPA National Health and 
Environmental Effects Research Laboratory 
approved the protocol for mouse use, which 
assured humane treatment and alleviation of 
suffering. Female C57BL/6 mice 4–6 weeks 
of age (Charles River Laboratory, Raleigh, 
NC) were acclimated in groups of three in a 
12/12-hr light/dark photocycle at 20–22°C. 
Mice had free access to rodent diet (TestDiet, 
Richmond, IN) and tap water that con-
tained < 11 μg/L As (Kenyon et al. 2008). 
Composition of AIN-93G purified rodent 
diet (Reeves et al. 1993) obtained from Dyets 
(Bethlehem, PA) is given in Supplemental 
Material, Table 1 (http://dx.doi.org/10.1289/
ehp.1003352). Soil-amended diets were pre-
pared by thorough mixing of test soil with 
powdered AIN-93G purified rodent diet to 
a 1% (wt/wt) soil:diet ratio. Arsenate (AsV)-
amended diet prepared by addition of sodium 
arsenate heptahydrate (Sigma, St. Louis, MO) 
to powdered AIN-93G purified rodent diet 
was used to determine the bioavailability of a 
freely soluble As salt. Diets were stored at 4°C 
until used.
At the start of an assay, three mice housed 
together during acclimation were transferred as 
a group to a metabolic cage that separated urine 
and feces (Nalgene, Rochester, NY). Twelve 
mice in four metabolic cages constituted an 
experimental run. Metabolic cages were main-
tained for 10 days under environmental condi-
tions given above with unlimited access to test 
diet and drinking water. For sample collection 
and data analysis, the unit of observation was 
the cage and the standard assay for a soil had 
a sample size of four (except soil 9, which had 
a sample size of three). To examine assay vari-
ability and reproducibility, bioavailability of As 
in soils 4 and 10 were assayed two and three 
times, respectively, over a 2-year period.
Daily food consumption for each cage 
was calculated as the difference between the 
weight of the food hopper immediately after 
each morning’s filling and before replenish-
ment the next morning. Cumulative food 
consumption for each cage was the sum of 
daily food consumption. Urine and feces were 
collected each morning from each metabolic 
cage. Combined body weights of the three 
mice in each metabolic cage were determined 
immediately before initial transfer into the 
metabolic cage and at termination. Mice 
were euthanized by carbon dioxide (CO2) 
  anesthesia on day 10.
Daily urine or feces collections for each 
cage were stored at –20°C until processed to 
produce a single cumulative urine sample and 
single cumulative feces sample. After thor-
ough mixing, multiple aliquots of the cumula-
tive urine sample for each cage were taken for 
determination of As concentration by INAA. 
Cumulative urinary excretion of As was calcu-
lated as the product of As concentration in the 
cumulative urine sample and the volume of 
the cumulative urine sample. Cumulative feces 
samples were homogenized with a freezer/mill 
(model 6850; Spex CertiPrep, Metuchen, NJ). 
Multiple aliquots of cumulative feces sample 
were taken for determination of As concentra-
tion by INAA. Cumulative fecal excretion of 
As was calculated as the product of As concen-
tration in the cumulative feces sample and the 
mass of the cumulative feces sample.
Absolute bioavailability (ABA) of As from 
ingestion of a soil- or AsV-amended diet was 
calculated as the ratio of cumulative excretion 
of As in urine and cumulative dietary intake 
Table 1. Description, elemental composition, and As speciation in test soils.a
Arsenic speciationb
Soil sourcec
Soil properties AsV AsIII
Reduced chi 
squaredg Soil ID Asd (mg/kg) Fee,f (g/kg) Mne,f (g/kg) Ale,f (g/kg) pHf Sorbed AsV (%) Scorodite (%) Realgar (%) Arsenopyrite (%)
1 Urban residential 990 20.9 0.5 11.8 6.1 52.0 21.2 26.8 — 0.004
2 Urban residential 829 20.5 0.7 9.4 6.3 96.7 3.3 — — 0.004
3 Urban residential 379 18.9 0.2 9.0 5.0 53.1 15.2 31.7 — 0.003
4 Smelter slag 837 294.4 2.7 13.2 7.2 18.7 1.6 47.7 32.1 0.001
5 Residential 244 46.0 0.8 21.7 7.3 96.2 3.8 — — 0.002
6 Residential 173 63.4 0.7 20.9 6.6 66.8 33.2 — — 0.002
7 Smelter slag 6,899 144.5 0.9 15.0 5.2 18.3 47.1 — 34.6 0.001
8 Residential 280 72.3 0.0 3.9 2.1 79.5 20.5 — — 0.007
9 Smelter slag 4,495 120.1 0.4 12.3 2.6 67.6 32.4 — — 0.011
10 NIST 2710 601 29.2 8.5 17.2 5.0 95.0 5.0 — — 0.007
11 NIST 2710a 1,513 34.0 1.7 10.0 4.0 66.8 23.2 9.9 — 0.01
aThe < 250 μm particle size fraction was used for all analyses. bDetermined by linear combination of As X-ray absorption spectroscopy. cSource of As-contaminated soil. dDetermined 
by INAA. eExtracted using U.S. EPA Method 3051A (U.S. EPA 2007d) and analyzed using U.S. EPA Method 6010C (U.S. EPA 2007e) by ICP-OES. fData represent the mean of duplicate 
analyses. gReduced chi-square values = (data – fit)2/data2.
Figure 1. Relationship between cumulative As 
intake and cumulative urinary As excretion (mean 
± SD). For soil numbers, see Table 1. Replicate 
assays are shown for soil 4 (4a, 4b) and soil 10 (10a, 
10b, 10c). NaAs, sodium arsenate–amended diet.
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of As (NRC 2003; U.S. EPA 2007c). ABA 
is commonly calculated and expressed on a 
percentage basis:
%ABA =  
(cumulative As excreted in urine ÷ 
cumulative As consumed) × 100,  [1]
with As measured in micrograms. Relative 
bioavailability (RBA) was calculated as the 
ratio of the ABA for As in a specific soil-
amended diet to the ABA for As in a diet 
containing sodium arsenate (NRC 2003; U.S. 
EPA 2007c). RBA is commonly expressed on 
a percentage basis:
%RBA =  
(ABA of As in a specific diet ÷ 
ABA of As in sodium arsenate) × 100. [2]
Bioaccessibility assays. For a full descrip-
tion of bioaccessibility assays, see Supplemental 
Material  (http://dx.doi.org/10.1289/
ehp.1003352). Bioaccessible As was deter-
mined using an in vitro method developed 
by the Solubility/Bioavailability Research 
Consortium (SBRC) assay (Kelly et al. 2002). 
In vitro assays were performed in triplicate for 
each soil and included addition of 1 g test soil 
to 100 mL gastric fluid consisting of 0.4 M 
glycine at pH 1.5 in a 125-mL high-density 
polyethylene bottle and rotating end over end 
in a water bath at 37°C for 1 hr. All soils tested 
in the bio  accessibility protocol were identical to 
those administered to mice in the in vivo stud-
ies and used in the mineralogy studies described 
above. All in vitro extraction solutions were 
refrigerated at 4°C for preservation and subse-
quent analysis by Inductively Coupled Plasma–
Optical Emission Spectroscopy (ICP-OES) 
(U.S. EPA 2007e).
In vitro bioaccessibility (IVBA) was calcu-
lated and expressed on a percentage basis:
%IVBA =  
(in vitro extractable mg As/kg soil ÷ 
total contaminant mg As/kg soil) × 100. 
  [3]
Statistical analysis. Simple linear regres-
sion was used to evaluate the relationship 
between in vivo As RBA data and IVBA data 
and to examine the effect of selected soil phys-
icochemical properties on As RBA and bioac-
cessibility. All analyses were performed using 
R software (version 2.9.1; R Development 
Core Team, Vienna, Austria), and figures 
were created using GraphPad Prism (version 
5.0; GraphPad, San Diego, CA).
Results
Soil characterization. Table 1 summarizes 
selected characteristics of test soils. Total As 
concentration in test soils ranged from 173 to 
6,899 /mg/kg. Arsenic speciation by oxidation 
state varied among soils [see Supplemental 
Material, Figure 1 (http://dx.doi.org/10.1289/
ehp.1003352)]. Soils 1, 3, 4, 7, and 11 had 
varying ratios of arsenite (AsIII) to AsV spe-
cies; soils 2, 5, 6, 8, 9, and 10 contained only 
AsV. We identified realgar in soils 1, 3, 4, and 
11 and arsenopyrite in soils 4 and 7. Sorbed 
AsV and scorodite are common As species in 
soil environments and often result from the 
oxidation of As ore materials such as realgar 
or arsenopyrite. Concentration ranges of iron 
(Fe), manganese (Mn), and aluminum (Al) in 
soils were 18.9–294.4 g/kg, 0–8.5 g/kg, and 
3.9–21.7 g/kg, respectively. Soil pH ranged 
from 2.1 to 7.3.
Mouse bioavailability assay. The gross 
clinical condition of mice was unaffected by 
ingestion of any of the amended diets; amend-
ment of diet with soil or sodium arsenate did 
not significantly affect cumulative diet con-
sumption (data not shown). Thus, amendment 
of AIN-93G rodent diet with 1% (wt/wt) soil 
or AsV did not affect diet palatability for mice. 
Mean cumulative consumption of As strongly 
correlated with the concentration of As in 
the diet [see Supplemental Material, Figure 2 
(http://dx.doi.org/10.1289/ehp.1003352)]. 
We evaluated mouse assay performance by 
determining the percentage of cumulative 
As intake recovered in cumulative urine and 
feces collections. Arsenic recoveries in excreta 
averaged 83.7% (range, 67–96%) for sodium 
arsenate–amended or soil-amended diets. 
For all dietary additives, percentage recovery 
and dietary As concentration were not corre-
lated (R2 = 0.227; p = 0.398, Pearson product 
moment correlation).
Increasing cumulative ingestion of As 
from amended diets was associated with 
increasing cumulative urinary excretion of As 
(Figure 1). Figure 2A shows As ABA estimates 
from diets amended with AsV, test soils, or 
SRMs. Duplicate assays with AsV-amended 
diet yielded an As ABA of approximately 60%. 
Arsenic ABA estimates for test soils ranged 
widely from approximately 7% to approxi-
mately 33%. Duplicate assays with diets 
amended with soil 4 (4a, 4b) yielded As ABA 
estimates of 6.7% and 7.1%. Triplicate assays 
with diets amended with National Institute 
of Standards and Technology’s NIST-2710, 
Montana Soil SRM (soils 10a, 10b, 10c), 
yielded As ABA estimates ranging from 25.9% 
to 27.2%. For comparison, NIST-2710a 
SRM-amended diets (soil 11) dosed at multi-
ple levels yielded an As ABA of approximately 
26% for each dose level [see Supplemental 
Material, Figure 2 (http://dx.doi.org/10.1289/
ehp.1003352)]. Figure 2B shows As RBA esti-
mates for test soils and SRMs. Relative to AsV 
bioavailability, As RBA estimates for test soils 
ranged from 11% to 53%. Arsenic RBA esti-
mates for NIST 2710–amended diet (soil 10) 
and NIST 2710a–amended diet (soil 11) were 
approximately 44%. Supplemental Material, 
Table 2, summarizes data from mouse assays.
Correlations among estimates of bioacces-
sibility and bioavailability and physicochemi-
cal properties. IVBA values ranged from 6.8% 
to 67% (SD were 0–3%). We extracted NIST 
SRMs (soils 10 and 11) multiple times over 
the course of the study in accordance with the 
SBRC assay (SDs were 4.1 and 1.7, respec-
tively). We used linear regression to assess 
predictability of As RBAs from bioaccessibil-
ity values derived from the SBRC assay. The 
derived regression model accounted for 92% 
of the variability in As bioavailability observed 
in the mouse assay (R2 = 0.92; Pearson cor-
relation = 0.96; Figure 3).
Figure 2. %ABA (A) and %RBA (B) of As from amended diets as a function of cumulative As intake 
(mean ± SD). Replicate assays are shown for soil 4 (4a, 4b) and soil 10 (10a, 10b, 10c); NaAs, sodium 
  arsenate–amended diet.
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Figure 3. Correlation between estimates of As bio-
accessibility and bioavailability (mean ± SD). %RBA 
= 0.72(%IVBA) + 5.64 (R2 = 0.92).
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We examined predictability of As bioavail-
ability or bioaccessibility from the physico-
chemical properties and speciation of As in 
soils by simple linear regression (Table 2). 
Physicochemical properties of soil that were 
significant predictors (p < 0.10) of As RBA 
estimates were also significant predictors of 
IVBA estimates, with the exception of percent 
arsenopyrite. Among predictors, sums of con-
centrations of extractable soil Fe and Al (Fe+Al) 
accounted for the largest amount of varia-
tion in RBA and IVBA estimates (R2 = 0.58 
and 0.40, respectively). Log(Fe+Al) improved 
the predictive value of this term (R2 = 0.80 
and 0.62 for RBA and IVBA, respectively). 
Although multivariable linear regression analy-
sis has been used to estimate As bioavailability 
(Yang et al. 2002), application of this method 
in the present study did not materially improve 
predictions of As RBA or IVBA.
Discussion
The concordance of RBA and bioaccessibil-
ity estimates obtained in mouse and in vitro 
assays with common physicochemical 
characteristics of soils suggested that these 
approaches could be used in a complemen-
tary manner to reduce uncertainty in assess-
ment of risk associated with exposure to 
As-contaminated soils.
The mouse assay proved adaptable for 
use with soils with a wide range of As con-
centrations and physicochemical proper-
ties. Amended diets were palatable, and as 
anticipated from earlier studies (Xie et al. 
2004), mice remained in apparent good 
health throughout the experimental period. 
In this study, calculation of the As ABA 
used results from the mouse assay for a diet 
amended with 7 ppm As as sodium arsenate. 
This amendment produced As dose levels of 
8.9 and 9.2 mg/kg in duplicate studies [see 
Supplemental Material, Tables 1 and 2 (http://
dx.doi.org/10.1289/ehp.1003352)]. The dose 
levels for AsV-amended diets exceeded those 
for contaminated soils 3, 5, 6, 8, and 10b; 
approximately equaled (i.e., with overlapping 
standard deviations) those for soils 4a, 4b, 
10a, and 10c; and was lower than those for 
soils 1, 2, 7, 9, and 11. Hence, for most soils 
tested, the concentration of AsV added to the 
diet equaled or exceeded that present in diet 
after soil amendment. Although additional 
studies with AsV-amended diets are needed to 
confirm that estimates of bioavailability of AsV 
or As in soil are unaffected by As concentra-
tion in amended diets, studies in AsV-treated 
laboratory mice suggest that dose level does 
not affect the rate of urinary clearance of As 
(Hughes and Thompson 1996; Hughes et al. 
1994; Kenyon et al. 2008). Similarities in the 
pattern and extent of urinary clearance of As 
in mice that have received sodium arsenate 
over a wide range of dose levels suggest that 
dose level does not influence uptake of AsV 
across the gastrointestinal barrier or its clear-
ance into urine. In the absence of a change in 
the rate of urinary clearance of As over a wide 
dose range, it is likely that mice ingesting diets 
amended with AsV or As-containing soils will 
reach whole-body steady-state body burden 
during the experimental period used in this 
study (Hughes et al. 2003).
Similar estimates of As bioavailability 
obtained for soils 4 and 10 in assays over a 
2-year period indicated that assay performance 
was stable (Figure 2A,B). In adult female mice 
receiving repeated daily oral doses of sodium 
arsenate, the body burden of As reaches steady 
state after 8 or 9 days of dosing (Hughes et al. 
2003, 2010). Under steady-state conditions, 
concentrations of As in tissues and outputs of 
As in urine and feces will reach plateau values 
that will remain unchanged throughout the 
dosing interval. Although concentrations of 
As in urine and feces are both good indica-
tors of current exposure, the predominance 
of urine as the route for As clearance after 
oral administration of inorganic As (Hughes 
et al. 2003) makes it ideal for estimating the 
extent of absorption of dietary As. Summing 
amounts of As excreted in urine and feces 
during the experimental period can be 
used to approximate recovery of As in the 
mouse assay. For the materials evaluated in 
the mouse assay, recoveries of ingested As in 
excreta ranged from 67% to 96%. However, 
these values should be regarded as minimal 
estimates because they do not include As that 
is retained in tissues of mice.
The mouse assay can be further refined by 
examining the role of dietary composition on 
the estimates of soil As bioavailability obtained 
with this model. Compared with AIN-93 
purified diets, the human diet common in 
developed countries derives more calories from 
fat, contains less fiber, and may not be optimal 
in terms of mineral and vitamin composition. 
These differences in dietary composition could 
affect the bioavailability of As in two ways. 
First, the elemental composition of the diet 
can affect As uptake across the gastrointestinal 
barrier. For example, an increasing concen-
tration of phosphate reduces in vitro uptake 
of AsV by Caco-2 intestinal cells derived 
from human colonic adeno  carcinoma cells 
(Calatayud et al. 2010) and gastrointestinal 
uptake of As in rats dosed orally with AsV 
(Gonzalez et al. 1995). Second, in humanized 
gnotobiotic mice the microbiota of the gastro-
intestinal tract is quickly altered by consump-
tion of a diet with a high fat and high sugar 
content (Turnbaugh et al. 2009). Alteration 
of the microbiota of the gastrointestinal tract 
produced by changes in dietary composition 
could alter gastrointestinal uptake of ingested 
AsV. Recent studies show that the anaerobic 
microbiota from the mouse cecum extensively 
metabolize AsV to produce inorganic thio-
arsenicals and methylated oxy- and thioarseni-
cals (Pinyayev et al. 2011). The mouse model 
can readily be adapted to examine effects of 
dietary composition of diets on the bioavail-
ability of As in soils.
Soil As RBA estimates obtained in juve-
nile swine and monkeys have ranged from 
0% to 52% (Casteel et al. 1997; Freeman 
et al. 1995; Lorenzana et al. 1996; Rees et al. 
2009; Roberts et al. 2002; Rodriguez et al. 
1999). Comparisons of As RBA data obtained 
in mice and juvenile swine are problematic 
because of differences in experimental design 
and dosing levels. However, four soils have 
been evaluated in both species. For three soils 
(soils 9, 10, and 11 in this study), As RBA 
estimates from mouse and juvenile swine dif-
fered by 4%, 0%, and 1%, respectively (U.S. 
EPA 2009). For the fourth soil (soil 8 in this 
study), As RBA estimates differed by 19.1% 
(with estimates of 40.9% for mouse and 60% 
for juvenile swine. Differences in As RBAs for 
mouse and juvenile swine may reflect physio-
logical differences between species. Additional 
soils should be evaluated in both species to 
identify possible sources of variability and 
permit a detailed comparison of the assays.
Table 2. Results of linear regression analyses to explore the influence of select soil properties on As RBA 
and IVBA.
RBA IVBA
Predictor Equation R2 p-Value Equation R2 p-Value
Sorbed AsV (%) 0.2x + 17.1 0.14 0.26 0.3x + 18.4 0.11 0.31
Scorodite (%) –0.4x + 38.9 0.10 0.35 –0.7x + 50.9 0.16 0.22
Realgar (%) 0.1x + 31.1 0.01 0.80 0.2x + 36.1 0.01 0.73
Arsenopyrite (%) –0.7x + 36.2 0.28 0.09* –0.7x + 42.5 0.16 0.23
AsV (%) 0.2x + 19.0 0.05 0.50 0.1x + 26.9 0.02 0.70
AsIII (%) –0.2x + 34.7 0.05 0.50 –0.1x + 40.2 0.02 0.70
As (mg/kg) x + 37.3 0.17 0.21 x + 45.2 0.15 0.23
Fe (g/kg) –0.1x + 43.5 0.48 0.02** –0.2x + 51.4 0.32 0.07*
Al (g/kg) –1.9x + 57.3 0.34 0.06* –2.7x + 73.3 0.32 0.07*
Mn (g/kg) 0.7x + 31.0 0.01 0.77 1.1x + 36.3 0.01 0.76
pH –2.2x + 43.3 0.05 0.52 –1.2x + 44.0 0.01 0.82
Fe+Al (mol/kg) –8.8x + 48.7 0.58 0.01# –10.5x + 57.9 0.40 0.04**
Log(Fe+Al) (mol/kg) –53.1x + 41.6 0.80 0.00# –67.5x + 50.1 0.62 0.00#
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A recent NRC report has recommended 
development and validation of in vitro assays 
that can replace in vivo assays and can provide 
reliable and accurate data that reduce uncer-
tainty in risk assessment (NRC 2007). This 
recommendation prompted development of 
bioaccessibility assays that reflect processes 
that control As bioavailability in the human 
gastrointestinal tract (Basta et al. 2007; Juhasz 
et al. 2007; Kelly et al. 2002; Rodriguez et al. 
1999; Ruby et al. 1999). High correlation (R2 
= 0.92, Pearson correlation = 0.96) between 
the As bioaccessibility data from the SBRC 
assay and As RBA estimates from the mouse 
assay is consistent with the high correlation 
of estimates of As RBA from juvenile swine 
with As bioaccessibility estimates from the 
SBRC assay (R2 = 0.75, Pearson correlation = 
0.87) (Juhasz et al. 2009). The correlation of 
findings from the SBRC assay and the mouse 
assay suggests that the bioaccessibility assay 
provides useful information about the charac-
teristics of As-containing soils that influence 
As RBA as measured in the mouse assay. In 
addition, strong agreement of estimates from 
the SBRC in vitro assay and the mouse assay 
suggest that the mouse assay can be used to 
validate performance of bioaccessibility assays.
Metal speciation and the concentra-
tions of Fe, Al, and Mn are known to affect 
solubilities and bioavailabilities of metals in 
soils (Bradham et al. 2006; Kelly et al. 2002; 
NRC 2003; Scheckel et al. 2009). In this 
study, we evaluated the effects of As specia-
tion and metal concentrations on estimates 
of soil As RBA and bioaccessibility obtained 
in the mouse assay and SBRC assay by lin-
ear regression analyses. We found significant 
inverse correlations between concentrations 
of extractable Fe and Al in soils and esti-
mates of soil As RBA and bioaccessibility. For 
example, the log-transformed sum of Fe+Al 
accounted for 80% and 62% of the variabil-
ity in estimates of As RBA and bioaccessibil-
ity, respectively. The high predictive value of 
log(Fe+Al) suggests that sorption of As to Fe 
and Al oxides reduces As solubilization and 
thereby reduces As RBA and bioaccessibil-
ity. Beak et al. (2006a, 2006b) found similar 
results for As bioaccessibility using a modi-
fied Rodriguez et al. (1999) in vitro method, 
which investigated As sorption on ferrihydrite 
[Fe3+
5O3(OH)9] and corundum (Al2O3). 
Thus, determination of the concentrations 
and forms of Fe and Al in soils may be use-
ful in assessing As bioavailability. Several clay 
minerals contain ferrous and ferric iron that, 
upon release via weathering, will form iron 
oxides and hydroxides in soil environments 
(Bowell 1994). Similar processes are also iden-
tified for aluminum and manganese oxides in 
soils (Jenne 1968; McKeague et al. 1971). 
Lower As RBA estimates for soils containing 
sulfide forms of As (realgar or arsenopyrite) 
may reflect slow dissolution kinetics of these 
mineral species. Although arsenopyrite was 
present in only two of the test soils, its pres-
ence significantly reduced As bioavailability 
estimates (p < 0.10). This finding is consistent 
with reports showing that As in arsenopyrite 
is bound tightly; therefore, As bioavailabil-
ity is likely to be low (Roberts et al. 2007). 
Additional studies would be useful to identify 
other metals and metalloids in soils that are 
potential modifiers of As bioavailability and 
bioaccessibility and to determine concentra-
tion dependencies of these interactions.
Conclusions
A multifaceted approach combining in vivo 
assays, in vitro assays, and physicochemical 
characterization of soils yielded comparable 
estimates of As bioavailability and provided evi-
dence of interrelations among physicochemical 
properties and estimates of As bioavailability. 
The range of As RBA estimates in this study 
(11–53%) implies that use of a default value of 
100% for As bioavailability in human health 
risk assessments may overestimate risk associ-
ated with exposure to As-contaminated soils. 
Further studies with the mouse assay and the 
in vitro assay coordinated with physiochemical 
characterization of test soils can confirm and 
extend the results obtained in this study and 
identify refinements in experimental design 
and data analysis that can improve the accuracy 
and reliability of estimates of bioaccessibility 
and bioavailability.
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